Quest Pharmatech Stock Analysis
| QPTFF Stock | USD 0.01 0.00 0.00% |
Quest PharmaTech holds a debt-to-equity ratio of 0.011. Quest PharmaTech's financial risk is the risk to Quest PharmaTech stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Quest PharmaTech's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Quest PharmaTech's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Quest Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Quest PharmaTech's stakeholders.
For many companies, including Quest PharmaTech, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Quest PharmaTech, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Quest PharmaTech's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Quest PharmaTech's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Quest PharmaTech is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Quest PharmaTech to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Quest PharmaTech is said to be less leveraged. If creditors hold a majority of Quest PharmaTech's assets, the Company is said to be highly leveraged.
Quest PharmaTech is overvalued with Real Value of 0.0112 and Hype Value of 0.0133. The main objective of Quest PharmaTech pink sheet analysis is to determine its intrinsic value, which is an estimate of what Quest PharmaTech is worth, separate from its market price. There are two main types of Quest PharmaTech's stock analysis: fundamental analysis and technical analysis.
The Quest PharmaTech pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Quest PharmaTech's ongoing operational relationships across important fundamental and technical indicators.
Quest |
Quest Pink Sheet Analysis Notes
About 17.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.19. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Quest PharmaTech recorded a loss per share of 0.39. The entity had not issued any dividends in recent years. Quest PharmaTech Inc., a pharmaceutical company, develops antibody based immunotherapeutic products for cancer. Further, the company develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications skin penetrating active molecules for cosmetic and pharmaceutical use and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest Pharmatech is traded on OTC Exchange in the United States.The quote for Quest PharmaTech is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Quest PharmaTech contact Ragupathy Madiyalakan at 780 448 1400 or learn more at https://www.questpharmatech.com.Quest PharmaTech Investment Alerts
| Quest PharmaTech generated a negative expected return over the last 90 days | |
| Quest PharmaTech has some characteristics of a very speculative penny stock | |
| Quest PharmaTech has accumulated 1000 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Quest PharmaTech has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Quest PharmaTech until it has trouble settling it off, either with new capital or with free cash flow. So, Quest PharmaTech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Quest PharmaTech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Quest to invest in growth at high rates of return. When we think about Quest PharmaTech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (85.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Quest PharmaTech has accumulated about 518.76 K in cash with (170.78 K) of positive cash flow from operations. | |
| Roughly 17.0% of Quest PharmaTech outstanding shares are owned by corporate insiders |
Quest Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.89 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Quest PharmaTech's market, we take the total number of its shares issued and multiply it by Quest PharmaTech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Quest PharmaTech, as well as the relationship between them.Quest PharmaTech Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Quest PharmaTech price series with the more recent values given greater weights.
Quest PharmaTech Debt to Cash Allocation
Many companies such as Quest PharmaTech, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Quest PharmaTech has accumulated 1000 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Quest PharmaTech has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Quest PharmaTech until it has trouble settling it off, either with new capital or with free cash flow. So, Quest PharmaTech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Quest PharmaTech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Quest to invest in growth at high rates of return. When we think about Quest PharmaTech's use of debt, we should always consider it together with cash and equity.Quest PharmaTech Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Quest PharmaTech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Quest PharmaTech, which in turn will lower the firm's financial flexibility.About Quest Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Quest PharmaTech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Quest shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Quest PharmaTech. By using and applying Quest Pink Sheet analysis, traders can create a robust methodology for identifying Quest entry and exit points for their positions.
Quest PharmaTech Inc., a pharmaceutical company, develops antibody based immunotherapeutic products for cancer. Further, the company develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications skin penetrating active molecules for cosmetic and pharmaceutical use and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest Pharmatech is traded on OTC Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Quest PharmaTech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Complementary Tools for Quest Pink Sheet analysis
When running Quest PharmaTech's price analysis, check to measure Quest PharmaTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest PharmaTech is operating at the current time. Most of Quest PharmaTech's value examination focuses on studying past and present price action to predict the probability of Quest PharmaTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest PharmaTech's price. Additionally, you may evaluate how the addition of Quest PharmaTech to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |